Hetero’s ‘Nirmacom’ is world’s first generic version of COVID-19 oral drug ‘PAXLOVID’ to receive WHO Prequalification
Hetero, India’s leading pharmaceutical company with the widest global reach, today announced the receipt of World Health Organization Prequalification of Medicines Program (WHO PQ) approval for its generic version of COVID-19 oral antiviral treatment candidate nirmatrelvir. This is the first prequalification for a generic version of Pfizer’s COVID-19 oral antiviral drug ‘PAXLOVID’, which the WHO […]
